Zoetis Inc. $ZTS Shares Sold by Baird Financial Group Inc.

Key Points

• Baird Financial Group reduced its Zoetis position by 14.5% in the second quarter, selling 22,396 shares and retaining 131,829 shares valued at approximately $9.5 million.
• Zoetis reported quarterly EPS of $1.87, slightly above the $1.85 analyst consensus, while revenue of $2.47 billion fell short of estimates and declined 0.2% year over year.
• Shares opened at $73.05, near their 12-month low, and analyst sentiment remained mixed: eight analysts rated the stock Buy, nine Hold, and two Sell, with a consensus price target of $101.08.

Baird Financial Group Inc. reduced its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 14.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,829 shares of the company's stock after selling 22,396 shares during the period. Baird Financial Group Inc.'s holdings in Zoetis were worth $9,473,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. California State Teachers Retirement System lifted its holdings in shares of Zoetis by 6,680.3% during the 2nd quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company's stock worth $3,430,982,000 after acquiring an additional 47,041,186 shares during the period. BlackRock Inc. lifted its holdings in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the last quarter. J. Stern & Co. LLP lifted its position in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. State Street Corp boosted its position in Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company's stock worth $2,490,845,000 after acquiring an additional 149,382 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company's stock worth $1,420,294,000 after acquiring an additional 189,235 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $73.05 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $150.05. The firm has a market cap of $30.19 billion, a PE ratio of 12.03, a PEG ratio of 1.70 and a beta of 0.73. The company's 50 day moving average price is $75.56 and its two-hundred day moving average price is $91.73.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the firm posted $1.76 EPS. The firm's quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $94.00 target price on Zoetis in a research report on Tuesday, August 25th. Piper Sandler dropped their price target on Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research report on Monday, August 10th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. TD Cowen reduced their price objective on Zoetis from $104.00 to $94.00 and set a "buy" rating on the stock in a research note on Tuesday, August 25th. Finally, UBS Group reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $101.08.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.